

The Progeria Research Foundation 9th International Scientific Workshop

September 20-22, 2018

Royal Sonesta Hotel in Cambridge, MA, USA



Thursday, September 20 Registration and Poster Set-up

2:00-4:00 PM	Registration in the West Tower, level two, Foyer in front of Grand Ballroom
2:00-4:00 PM	Poster Set-up: All poster presenters (Sessions 1 and 2) are asked to set up their posters at this time in the West Tower, level two, Skylines A-E

Thursday, September 20 Day 1 Kickoff Session: 4:00 PM – 9:30 PM, Grand Ballroom Dinner Included

4:00-4:30 PM	Introduction & Greetings: Medical Director Leslie Gordon, MD, PhD, PRF Executive Director Meryl Fink, Esq; Board Chair Scott Berns, MD	
4:30-5:30	Sammy, Amerigo and Laura Basso, Italy	Patient and Parent Perspective: Living with Progeria, participating in clinical trials
5:30-5:40	Francis Collins, MD, PhD National Institutes of Health	Plenary Speaker Introduction
5:40-6:20	Eric S. Lander, PhD - Harvard Medical School; the Broad Institute of MIT and Harvard	New Genomic Approaches for Understanding Disease
6:25	<i>DINNER IS SERVED</i>	

Friday, September 21

Day 2: Breakfast Buffet / 7:00 AM – 7:55 AM, Grand Ballroom
All Posters should be set up by start of morning session.

Day 2 Morning Session

Moderator: Vicente Andrés García, CNIC

8:00-9:15	Meeting Program Overview & Intro. To Progeria	Leslie Gordon
9:20-9:50	Juan Carlos Belmonte Izpisua The Salk Institute for Biological Studies, La Jolla, CA	CRISPR/Cas gene editing in HGPS mice
9:50-10:20	Nicolas Levy University of Marseille, Inserm, France	MG132-induced progerin clearance is mediated by autophagy activation and splicing regulation in Progeria
10:20-10:40	BREAK	
10:40-11:10	Vicente Andrés García, PhD Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain	Molecular and cellular mechanisms governing cardiovascular disease and aging in HGPS
11:15-11:45	Isabella Saggio – Dept. Biology and Biotechnology "C. Darwin" Sapienza University of Rome, Italy	The lamin-interacting telomeric protein AKTIP in HGPS
11:50-12:20	Lightening Poster Session – Odd numbered	1 minute & 1 slide per poster presenter
12:30-1:30	LUNCH	

Day 2 Afternoon Session

Cardiovascular Disease in HGPS

Moderator: Mark Kieran, Dana Farber Cancer Institute, Boston

1:35-2:05	Ashwin Prakash Boston Children's Hospital, Boston	Cardiac and Echocardiographic Manifestations in Progeria, and effect of Lonafarnib on Disease
2:10-2:40	Srinivasan Mukundan Brigham and Women's Hospital, Boston	Novel Brain MRI Disease Findings in Progeria
2:45-3:15	Richard K. Assoian Institute of Translational Medicine and Therapeutics, University of Pennsylvania	Extracellular Matrix remodeling and arterial stiffening in HGPS: lessons from the LMNA G609G mouse
3:20-3:50	7th INNING STRETCH and Networking Time	
3:55-4:25	Roland Foisner Max F. Perutz Laboratories, Medical University, Vienna	Progerin Expression in Endothelial Tissue Impairs Nucleocytoskeletal Coupling and Causes Cardiovascular Pathology
4:30-5:00	Lightening Poster Session- Even numbered	1 minute & 1 slide per poster presenter

ADJOURN UNTIL DINNER AND EVENING SESSION

6:00–8:00 PM Buffet Dinner/Informal Conversation, Grand Ballroom

Day 2 Evening Session: Formal Poster Session #2 - Skylines A-E

6:30-8:00	Even-Numbered Posters Formally Presented
8:00-9:30	Odd-Numbered Posters Formally Presented

Saturday, September 22
Day 3: Breakfast Buffet / 7:15 AM – 8:10 AM, Grand Ballroom

Day 3 Morning Session

Current and Future Treatments and Trials
Moderator: Tom Misteli, National Cancer Institute, NIH

8:15-8:45	Monica Kleinman – Boston Children’s Hospital	Phase 1 Results: Ongoing Everolimus plus Lonafarnib Clinical Trial
8:45-9:15	Ralph D’Agostino, Sr. and Joe Massaro Boston University, Boston, MA	Statistical Challenges in Trial Design and Outcome Measures for Progeria
9:15-9:45	Leslie Gordon Boston Children’s and Hasbro Children’s Hospitals	Biochemical Biomarker Development in Progeria
9:45-10:15	BREAK	
10:15-10:45	Francis Collins National Institutes of Health, Bethesda, MD	Progeria: from basic science insights to therapeutic opportunities
10:50-11:20	Tom Misteli	RNA as a therapeutic target in HGPS
11:25-11:55	Silvia Ortega Gutiérrez Medicinal Chemistry Laboratory Av Complutense, Madrid, Spain	New Isoprenylcysteine carboxymethyltransferase (ICMT) Inhibitors for the Treatment of Progeria
12:00-1:00	LUNCH	

Day 3 Afternoon Session

Molecular and Cellular Mechanisms in HGPS and Aging

Moderator:

1:00-1:30	TBD	
1:35-2:05	Toren Finkel – Aging Institute, Pittsburgh, PA	Vascular Autophagy and Hutchinson-Gilford Progeria
2:10-2:40	Carlos Lopez-Otín (Tentative) Universidad De Oviedo, Spain	NF-κB Signaling as a Driver of Progeria and Ageing
2:45-3:15	LATE BREAKING DATA PRESENTATIONS	
3:20-3:50	BREAK	
3:50-4:40	Summation of Meeting and Key Findings	

Thank you for coming!

The 2018 PRF Progeria Workshop Organizing Committee

Leslie B. Gordon, MD, PhD (Chair) - *Medical Director, The Progeria Research Foundation (PRF); Professor of Pediatrics, Hasbro Children’s Hospital and The Warren Alpert Medical School of Brown University*

Tom Misteli, PhD – *Senior Deputy Director for Research, Center for Cancer Research, NCRI, NIH*

Vicente Andrés García, PhD – *Professor, Laboratory of Molecular and Genetic Cardiovascular Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares Carlos III*

Mark Kieran, MD, PhD – *Professor, Dana Farber Cancer Institute, Harvard University, Boston, MA*

Meryl Fink, Esq – *President and Executive Director, PRF*

Maria Sullivan – *Continuing Medical Education Director, The Warren Alpert Medical School of Brown University*

Donnalynn Gibson (Meeting Coordinator) – *Executive Administrative Assistant to the Medical Director, PRF*